By the time friction between Medical and Commercial teams becomes visible in a rare disease launch, the causes are often already embedded. Trial design, unclear ownership, weak insight systems and leadership behaviours that prioritise internal processes over external understanding all shape the trajectory of adoption long before launch begins. True alignment builds momentum for launch, with activities compounding to create greater impact rather than just complementing one another.
In May 2026, Spectrum Science hosted a roundtable at the Medical Affairs Professional Society (MAPS) EMEA Annual Meeting with nine senior global Medical Affairs leaders, representing organisations ranging from small to worldwide. The question was direct: how can Medical and Commercial teams stay aligned amid real-world launch constraints? The answers pointed to a clear conclusion: alignment does not fail at launch; it breaks much earlier. Rare disease launches do not fail because teams are misaligned on activity. They fail because we are not focused on whether those activities are cohesively building toward a change in clinical practice.
Alignment is a cultural output, not a process input
The strongest view in the room was that launch excellence frameworks do not create genuine Medical-Commercial alignment. Alignment must originate from within leadership culture. When teams are measured on activity but judged on outcomes, alignment becomes performative rather than genuine.
When senior leaders, including the C-suite, are visibly patient-centred in how they allocate resources and make decisions, not just in how launch frameworks are worded or KPIs tracked, alignment follows. When leadership is fragmented or ambiguous, no cross-functional process can compensate.
In rare diseases, the stakes are higher. Patient communities are small, expert clinicians are scarce and every interaction carries reputational weight. A single inconsistency between Medical and Commercial narratives can undo months of relationship-building and in an era of instant access to information, inconsistencies surface quickly.
Where alignment breaks before launch
- Clinical development is an upstream problem
The most common alignment failure was not between Medical and Commercial, but between Medical and Clinical Development. Trials designed around US FDA endpoints can leave gaps for European HTA. Medical Affairs is then asked to launch with data that does not answer payer questions.
The fix can be organisationally difficult: Medical Affairs must co-author clinical development plans, not conduct post hoc reviews. This is not just about access to data; it is about shaping the clinical narrative early enough for it to change clinical practice. The window to influence endpoint selection closes well before phase 3 enrolment begins.
- The insight loop fails before launch
Participants agreed that insights from MSLs, Medical Information, congresses, advisory boards and patients are strategically critical. Yet without a clear way to translate those insights into action, they rarely build the kind of momentum needed to shift behaviour.
Yet systems for capturing, synthesising and acting on them are often inadequate.
The causes are structural: time pressure, inconsistent customer relationship management (CRM) adoption and different definitions of a genuine insight. Most damaging is the ‘black box’ problem. Valuable face-to-face interactions disappear because they are never formally recorded. As AI synthesis tools become standard, their output will only be as good as the data captured.
In genuinely unmapped rare diseases, this is compounded further. Pre-defining categories too early risks filtering out the most important signals. Insight capture should be phased: open and broad before launch, then structured once the landscape becomes clearer.
- Ownership ambiguity concentrates in three domains
Participants identified three recurring sources of friction: data dissemination (publications, congress strategy, medical education); external stakeholder engagement (including experts, patient advocacy and payers), and safety communications.
In rare diseases, these are acutely sensitive. The same expert clinician may be an external medical expert, a commercial speaker and an advisory board member, encountering both Medical and Commercial around the same time.
Ownership must be defined before launch pressure arrives because as that pressure builds, ambiguity doesn’t just create friction; it drives poor decision-making, slows execution and ultimately compresses the window to improve patient outcomes.
The cost of looking inward
Teams are often drowning in internal reporting, consultant-led launch frameworks and cross-functional meeting cycles precisely when external understanding matters most. In that environment, momentum stalls, not because teams lack activity, but because they lack a clear link between effort and impact.
Medical Affairs’ unique value in rare disease, scientific relationships with expert physicians, proximity to patient communities and real-time field insights depend on time spent externally. AI can expedite some processes, but it cannot replace trusted interaction. Internal reporting that drives no actionable decision is an opportunity cost that is rarely quantified and rarely discussed.
What should Medical Affairs leaders do next?
The strategic lesson is not that rare disease launches need more meetings, more reporting, or more launch theatre. They need earlier medical input, clearer decision-making and greater discipline in determining what creates value. Not just in what gets done, but in what can meaningfully improve patient outcomes
Three moves stand out:
- Do now: Secure formal input into evidence generation, endpoint selection and real-world evidence plans before the window closes
- Do next: Build the pre-launch architecture for insight capture, synthesis and cross-functional decision-making, with clear definitions and decision rights
- Stop doing: Letting internal reporting, legacy launch frameworks and proxy KPIs consume time that should be used to build external understanding and scientific credibility.
The reframe that resonated clearly was simple: stop treating Medical-Commercial alignment as a coordination problem and start treating it as shared ownership of commercialisation. Because alignment is not proven by whether teams are coordinated, it is proven by whether their combined efforts are sustained through to changing clinical practice to improve patient outcomes and in doing so, building real, lasting momentum.
Spectrum Science partners with leading biotechs and pharmaceutical companies on rare disease launch strategy, scientific communication and cross-functional alignment. Get in touch to explore how we can support your team.
